Highline Wealth Partners’s BioNTech BNTX Stock Holding History

Highline Wealth Partners’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3	Closed	-$273	–	915
2025 Q1	$273	Buy	+3	New	+$336	﹤0.01%	917

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Highline Wealth Partners's BNTX Position: Q2 2025 in Review

Highline Wealth Partners sold out of BioNTech (BNTX) in Q2 2025, closing a stake of 3 shares — an estimated $273 sold.

Highline Wealth Partners first reported a position in BNTX in Q1 2025 and held it in 1 quarter. The position peaked at $273 in Q1 2025. 258 funds tracked by Wall St. Rank hold BNTX as of Q2 2025.

Highline Wealth Partners reported no remaining BioNTech position as of Q2 2025 after selling out during the quarter.
Highline Wealth Partners sold 3 BioNTech shares in Q2 2025, an estimated $273.
Highline Wealth Partners first reported a position in BioNTech in Q1 2025 and held it in 1 quarter.
Highline Wealth Partners's BioNTech position peaked at $273 in Q1 2025.
258 funds tracked by Wall St. Rank held BioNTech as of Q2 2025.

Based on Highline Wealth Partners's 13F filing for Q2 2025, filed 16 Jul 2025.